Cargando…

Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics

BACKGROUND AND OBJECTIVE: Schizophrenia and Alzheimer’s disease are characterised by abnormalities in glutamatergic pathways related to N-methyl-d-aspartate receptor hypofunction. Glycine is an N-methyl-d-aspartate receptor co-agonist; inhibition of glycine transporter 1 may improve N-methyl-d-aspar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moschetti, Viktoria, Schlecker, Christina, Wind, Sven, Goetz, Sophia, Schmitt, Holger, Schultz, Armin, Liesenfeld, Karl-Heinz, Wunderlich, Glen, Desch, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061410/ https://www.ncbi.nlm.nih.gov/pubmed/29846887 http://dx.doi.org/10.1007/s40261-018-0660-2

Ejemplares similares

Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies
por: Rosenbrock, Holger, et al.
Publicado: (2018)

Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia
por: Rosenbrock, Holger, et al.
Publicado: (2023)

Safety, Tolerability and Pharmacokinetics of Oral BI 425809, a Glycine Transporter 1 Inhibitor, in Healthy Male Volunteers: A Partially Randomised, Single-Blind, Placebo-Controlled, First-in-Human Study
por: Moschetti, Viktoria, et al.
Publicado: (2017)

Efficacy and safety of the novel GlyT1 inhibitor BI 425809 in Alzheimer’s dementia: a randomized controlled trial
por: Wunderlich, Glen, et al.
Publicado: (2023)

The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [(14)C]-BI 425809 in Healthy Males
por: Burkard, Ute, et al.
Publicado: (2021)

Correction to: The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [(14)C]‑BI 425809 in Healthy Males
por: Burkard, Ute, et al.
Publicado: (2022)

Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor
por: Desch, Michael, et al.
Publicado: (2021)

Pharmacokinetic-Interactions of BI 425809, a Novel Glycine Transporter 1 Inhibitor, With Cytochrome P450 and P-Glycoprotein Substrates: Findings From In Vitro Analyses and an Open-Label, Single-Sequence Phase I Study
por: Desch, Michael, et al.
Publicado: (2023)

Synergistic Control of Transmitter Turnover at Glycinergic Synapses by GlyT1, GlyT2, and ASC-1
por: Eulenburg, Volker, et al.
Publicado: (2022)

GlyT2+ Neurons in the Lateral Cerebellar Nucleus
por: Uusisaari, Marylka, et al.
Publicado: (2009)

Pharmacological Evidence on Augmented Antiallodynia Following Systemic Co-Treatment with GlyT-1 and GlyT-2 Inhibitors in Rat Neuropathic Pain Model
por: Mohammadzadeh, Amir, et al.
Publicado: (2021)

Glycinergic transmission: glycine transporter GlyT2 in neuronal pathologies
por: Zafra, Francisco, et al.
Publicado: (2016)

Calnexin-Assisted Biogenesis of the Neuronal Glycine Transporter 2 (GlyT2)
por: Arribas-González, Esther, et al.
Publicado: (2013)

Bidirectional Modulation of Nociception by GlyT2(+) Neurons in the Ventrolateral Periaqueductal Gray
por: Assareh, Neda, et al.
Publicado: (2023)

The presynaptic glycine transporter GlyT2 is regulated by the Hedgehog pathway in vitro and in vivo
por: de la Rocha-Muñoz, Andrés, et al.
Publicado: (2021)

Membrane cholesterol regulates inhibition and substrate transport by the glycine transporter, GlyT2
por: Frangos, Zachary J, et al.
Publicado: (2023)

Identification of a 3(rd) Na(+) Binding Site of the Glycine Transporter, GlyT2
por: Subramanian, Nandhitha, et al.
Publicado: (2016)

Glycinergic Transmission in the Presence and Absence of Functional GlyT2: Lessons From the Auditory Brainstem
por: Brill, Sina E., et al.
Publicado: (2021)

Startle disease in Irish wolfhounds associated with a microdeletion in the glycine transporter GlyT2 gene
por: Gill, Jennifer L., et al.
Publicado: (2011)

PKC-Dependent GlyT1 Ubiquitination Occurs Independent of Phosphorylation: Inespecificity in Lysine Selection for Ubiquitination
por: Barrera, Susana P., et al.
Publicado: (2015)

Correction: Identification of a 3(rd) Na(+) Binding Site of the Glycine Transporter, GlyT2
por: Subramanian, Nandhitha, et al.
Publicado: (2016)

The GlyT1 Inhibitor Bitopertin Ameliorates Allodynia and Hyperalgesia in Animal Models of Neuropathic and Inflammatory Pain
por: Armbruster, Anja, et al.
Publicado: (2018)

Identification of an allosteric binding site on the human glycine transporter, GlyT2, for bioactive lipid analgesics
por: Mostyn, Shannon N, et al.
Publicado: (2019)

Further characterization of the GlyT-1 inhibitor Org25935: anti-alcohol, neurobehavioral, and gene expression effects
por: Lidö, Helga Höifödt, et al.
Publicado: (2017)

MS Binding Assays for Glycine Transporter 2 (GlyT2) Employing Org25543 as Reporter Ligand
por: Ackermann, Thomas M., et al.
Publicado: (2020)

Constitutive Endocytosis and Turnover of the Neuronal Glycine Transporter GlyT2 Is Dependent on Ubiquitination of a C-Terminal Lysine Cluster
por: de Juan-Sanz, Jaime, et al.
Publicado: (2013)

Expression of functional inhibitory neurotransmitter transporters GlyT1, GAT-1, and GAT-3 by astrocytes of inferior colliculus and hippocampus
por: Ghirardini, Elsa, et al.
Publicado: (2018)

Modification of a Putative Third Sodium Site in the Glycine Transporter GlyT2 Influences the Chloride Dependence of Substrate Transport
por: Benito-Muñoz, Cristina, et al.
Publicado: (2018)

E3 ubiquitin ligases LNX1 and LNX2 are major regulators of the presynaptic glycine transporter GlyT2
por: de la Rocha-Muñoz, A., et al.
Publicado: (2019)

Molecular and Electrophysiological Characterization of Dorsal Horn Neurons in a GlyT2-iCre-tdTomato Mouse Line
por: He, Xiaolan, et al.
Publicado: (2021)

Bupivacaine reduces GlyT1 expression by potentiating the p-AMPKα/BDNF signalling pathway in spinal astrocytes of rats
por: Lu, Kaimei, et al.
Publicado: (2022)

Efficacy and safety of iclepertin (BI 425809) in patients with schizophrenia: CONNEX, a Phase III randomised controlled trial programme
por: Falkai, P., et al.
Publicado: (2023)

Quantitative electroencephalography parameters as neurophysiological biomarkers of schizophrenia-related deficits: A Phase II substudy of patients treated with iclepertin (BI 425809)
por: Schultheis, Christian, et al.
Publicado: (2022)

Maternal Separation Alters Ethanol Drinking and Reversal Learning Processes in Adolescent Rats: The Impact of Sex and Glycine Transporter Type 1 (GlyT1) Inhibitor
por: Filarowska-Jurko, Joanna, et al.
Publicado: (2022)

Evaluation of the Efficacy of BI 425809 Pharmacotherapy in Patients with Schizophrenia Receiving Computerized Cognitive Training: Methodology for a Double-blind, Randomized, Parallel-group Trial
por: Harvey, Philip D., et al.
Publicado: (2020)

S40. COMBINING PHARMACOTHERAPY OF BI 425809 WITH COMPUTERISED COGNITIVE TRAINING IN PATIENTS WITH SCHIZOPHRENIA: INITIAL EXPERIENCE OF A LARGE-SCALE MULTICENTRE RANDOMISED CLINICAL TRIAL
por: Hake, Sanjay, et al.
Publicado: (2020)

Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis
por: Maher, Toby M., et al.
Publicado: (2022)

Association study of the excitatory amino acid transporter 2 (EAAT2) and glycine transporter 1 (GlyT1) gene polymorphism with schizophrenia in a Polish population
por: Merk, Wojciech, et al.
Publicado: (2019)

QSAR, ADMET In Silico Pharmacokinetics, Molecular Docking and Molecular Dynamics Studies of Novel Bicyclo (Aryl Methyl) Benzamides as Potent GlyT1 Inhibitors for the Treatment of Schizophrenia
por: El fadili, Mohamed, et al.
Publicado: (2022)

GlyT2-Dependent Preservation of MECP2-Expression in Inhibitory Neurons Improves Early Respiratory Symptoms but Does Not Rescue Survival in a Mouse Model of Rett Syndrome
por: Hülsmann, Swen, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qf9rlc8qvh36pkur8ff6lhanh2